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Abstract
Background: We conducted a case-control study to evaluate the role of UDP-
glucuronosyltransferase 1A7 (UGT1A7) polymorphisms in the onset of hepatocellular carcinoma
(HCC).
Methods: The study included 165 patients with HCC, 134 with cirrhosis and 142 controls without
liver disease, matched for age and hospital. All were men younger than 75 years. HCC and cirrhosis
patients were stratified according to time since cirrhosis diagnosis.
Results: We found a positive association between the UGT1A7*3/*3 genotype and HCC when
the comparison was restricted to patients whose disease was of viral origin [OR = 3.4 (0.3–45)]
but a negative association when it included only alcoholic patients [OR = 0.1 (0.02–0.6), p = 0.01].
Conclusion: Our study shows that UGT1A7 may play a role in hepatocellular carcinogenesis and
that this role may differ according to the primary cause of the cirrhosis.
Background
Hepatocellular carcinoma (HCC) is a major cancer in
developing countries. Etiologically it is a multifactorial
disease that has been linked to both viral and chemical
carcinogens. Established causal risk factors include hepa-
titis B (HBV) infection, dietary aflatoxin exposure, chronic
alcohol consumption, and cirrhosis of the liver [1]. IARC
recently listed smoking as a cause of liver cancer, although
the dose-effect relation is not firmly established [2]. Hep-
atitis C virus (HCV) also appears to have contributed to
the increasing incidence of HCC in North America and
Europe over the past two decades and will probably
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become the dominant viral cause of this cancer in these
low-risk regions. In France, around 90% of HCC occur on
cirrhotic livers, with heavy drinking the principal causal
factor.
Accumulating evidence indicates that susceptibility to
cancer is mediated by genetically determined differences
in the effectiveness of carcinogen detoxification. Various
epidemiologic studies have examined the role in HCC of
different polymorphisms [3], including UDP-glucurono-
syltransferase 1A7 (UGT1A7) [4-6].
The human UDP-glucuronosyltransferases (UGTs) are an
enzyme superfamily that metabolizes endogenous com-
pounds such as bilirubin, steroid hormones and environ-
mental carcinogens including tobacco-specific
nitrosamines and benzo(a)pyrene by glucuronidation
reaction [7]. Nine alleles of UGT1A7 have been described:
alleles *3 and *4 are associated with decreased enzyme
activity and allele *2 with an activity similar to the wild-
type allele *1 [7]. The relation between the UGT1A7 pol-
ymorphism and HCC was first investigated by Vogel et al
in a German population [4]. In that study, subjects carry-
ing one allele with a low detoxification capacity
(UGT1A7*3) were at higher risk of HCC. Two subsequent
studies have confirmed this result in different popula-
tions, one Japanese and the other Taiwanese [5,6]. Other
epidemiological studies of different cancer sites also sug-
gest that low UGT1A7 detoxification activity is associated
with a higher risk of cancer [8-12]; one study was unable
to confirm this result [13].
The case-control study reported here sought to evaluate
the role of UGT1A7 polymorphisms in the onset of HCC.
Since almost all HCC cases occur in cirrhotic liver, we con-
sidered 2 control groups, one with no liver disease and
one with cirrhosis and no liver cancer.
Methods
The study took place in the hepatology departments of 4
hospitals, 3 in the Paris area and 1 in eastern France
(Nancy). Subjects (HCC cases, cirrhosis patients and con-
trols) were recruited prospectively from March 2000 to
August 2003.
HCC cases
Eligible cases were patients aged 75 years or younger, born
in Europe of parents born in Europe, admitted to one of
the participating departments and newly diagnosed with
primary HCC, on the basis of either histologic analysis or
the combination of focal lesions detected by any imaging
technique and an alpha feto-protein (AFP) level > 250 ng/
ml. Of the 220 eligible HCC patients identified, 165
(75%) were interviewed (20 refused to participate, 7 died
and 28 were lost to follow-up before they could be
included). Of those interviewed, 151 (91.5%) had serum
samples tested for hepatitis B surface antigen (HbsAg) and
antibodies to HCV (anti-HCV).
Cirrhosis patients
Patients with cirrhosis but not HCC were recruited in the
same departments as the cancer patients. Cirrhosis was
defined either by histology or by the combination of clin-
ical, laboratory, and endoscopic signs. The absence of
HCC was established by the absence of focal lesions on
imaging and by an AFP level < 10 ng/ml. Cirrhosis
patients were stratified in 3 classes according to time since
cirrhosis diagnosis: i) subjects with newly-detected cirrho-
sis were matched for age (± 5 years) with cases whose cir-
rhosis was diagnosed at the same time as the carcinoma,
ii) subjects with cirrhosis diagnosed within the past 5
years, matched for age with HCC cases whose cirrhosis
had been diagnosed for more than 1 and fewer than 5
years, and iii) subjects with cirrhosis diagnosed for more
than 5 years, matched for age with HCC cases whose cir-
rhosis had also been diagnosed more than 5 years earlier.
We preferred complying with this stratification criterion,
even if age matching then failed, because we thought that
it was most important to avoid comparing new cirrhosis
patients with HCC patients whose cirrhosis had begun
long ago.
We tested serum samples of the cirrhosis patients for the
presence of hepatitis B surface antigen (HbsAg) and anti-
bodies to HCV (anti-HCV), as we had for the HCC
patients.
Controls
Controls without liver disease were recruited in different
hospital departments at the same time as the cases. Each
time a new HCC patient was included in the study, we
sought a control subject who met the matching criteria
(age ± 2.5 years and hospital) and the additional inclu-
sion criteria: no history of cancer and well enough to pro-
vide a blood sample. We systematically took the first
person who met these criteria. Nearly all agreed to partic-
ipate; when they did not, we took the next eligible control
who did. This control group comprised patients with a
total of 51 different diagnoses including coloscopy
(17%), diseases of the circulatory system (40%), diseases
of the digestive system (11%), diseases of the muscu-
loskeletal system and connective tissue (10%), and finally
diverse diseases, each representing less than 10%. The
mean number of patients per diagnosis was 3 (min = 1
max = 22 admitted for coloscopy).
Written informed consent was obtained from all subjects
and study approval was granted by the institutional ethics
committeeBMC Cancer 2007, 7:214 http://www.biomedcentral.com/1471-2407/7/214
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Questionnaire data
All HCC patients, cirrhosis patients, and controls were
interviewed face-to-face in the hospital, according to a
questionnaire that asked for information about social and
demographic characteristics and then for specific informa-
tion about lifetime tobacco use. A food frequency ques-
tionnaire completed the interview. It included questions
about beverages, alcoholic and nonalcoholic. Subjects
were asked about the frequency of their consumption of
beer, wine, and spirits. On the assumption that a glass of
beer (250 ml), a glass of wine (120 ml), a "strong" spirit
(i.e., whisky) (4 ml), and a "lighter" spirit (i.e., port) (12
ml) had respective ethanol contents of 8.75 g, 9.6 g, 9.38
g, and 6.08 g, we converted alcoholic beverage consump-
tion into grams of pure ethanol to obtain a cumulative
lifetime ethanol dose and then divided by the total dura-
tion of alcoholic beverage consumption for a mean
weekly consumption, which we expressed as drinks per
day. Because the food frequency questionnaire was not
available at the beginning of the study, the first 50 subjects
did not complete it, and the alcohol variable is missing for
them.
DNA bank and genotyping
DNA extraction
Genomic DNA was purified from human lymphocytes
(HCC cases and cirrhosis patients and controls) with a
commercial kit (Qiagen, Courtabœuf, France) and stored
at -20°C until use.
DNA (10–50 ng/μl) was used for polymerase chain reac-
tion (PCR). All PCRs were performed in a 25-μl reaction
volume containing 2 μl of DNA, 2.5 μl of 10× PCR buffer
(GeneAmp, Applied Biosystems, Courtabœuf, France),
MgCl2 (GeneAmp, Applied Biosystems) at various final
concentrations, 200 μM dNTPs (ABgene, Courtabœuf,
France), 400 nM of each primer (Genset, Paris, France)
and Taq Polymerase (AmpliTaq DNA Polymerase, Applied
Biosystems). PCR was performed in a DNA thermal cycler
(Applied Biosystems). The amplified products (5 μl) were
electrophoresed in 1.5% agarose gel (Invitrogen, Cergy
Pontoise, France) and visualized by ethidium bromide
staining.
The UGT1A7 protein sequences differ at amino acid posi-
tions 129, 131 and 208. The various combinations create
four distinct allelic variants in human populations:
UGT1A7*1 (N129R131W208), *2 (K129K131W208), *3
(K129K131R208) and *4 (N129R131R208). Haplotype
analysis revealed that the polymorphisms at position 129
and 131 are in complete disequilibrium linkage, whereas
the polymorphism at position 208 occurs independently
[14]. Based on these data, two polymorphisms (e.g.,
N129K and W208R) were detected for the UGT1A7 geno-
typing.
The single nucleotide polymorphisms (SNPs) of UGT1A7
(N129K and W208R) were detected by using a 5' nuclease
allelic discrimination assay (ABI PRISM 7700 Sequence
Detection System; Applied Biosystems, Foster City, CA).
The following sequences were used for the primers for
amplification of PCR fragments containing SNPs of the
UGT1A7 gene and for specific probes (for allelic discrimi-
nation):
N129K Forward: 5'-CACCATTGCGAAGTGCATTT-3'
(AAT->AAG) Reverse 5'-GGATCGAGAAACACTGCAT-
CAA-3'
Probe N129 5'-CAGGAGTTTGTTTAATGAC-3'
Probe K129 5'-CAGGAGTTTGTTTAAGGAC-3'
W208R Forward: 5'-CCAGACTTCTCTTAGGGTTCT-
CAGA-3'
(TGG->CGG) Reverse 5'-CAGAGGCTATTTCTAAGA-
CATTTTTGA-3'
Probe W208 5'-CATGATGTGGTTCCATAC-3'
Probe R208 5'-CATGATGTGGTTCCGTAC-3'
Specific probes for each allele were labeled with the fluo-
rescence reporter dyes FAM and VIC at their 5' extremities.
We classified these alleles into 3 groups on the basis of
their enzymatic activity *1/*1 or *1/*2 or *2/*2: high
activity, *1/*3 or *2/*3 intermediate activity, *3/*3: low
activity [7].
Statistical Method
All statistical analyses were performed using STATA soft-
ware. Odds ratios (OR) and their 95% confidence inter-
vals (95% CI) were calculated with unconditional logistic
regression including the matching variables of age and
hospital as well as the standard risk factors (such as
drinks/day) for the comparison between cases and con-
trols and time since cirrhosis diagnosis (in years), cirrho-
sis characteristics (heavy drinkers-virus(-), virus(+)), and
social class (blue- or white-collar workers) for the compar-
ison between the HCC cases and the cirrhosis controls.
The role of UGT1A7 was tested for each genotype, with the
genotype *1/*1 as the reference category, and then for
each phenotype, with high enzyme detoxification activity
as the reference category. The phenotypic classification
that we have adopted pools the *1/*1 or *1/*2 or *2/*2
to define subjects with a high activity, those with geno-BMC Cancer 2007, 7:214 http://www.biomedcentral.com/1471-2407/7/214
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types *1/*3 or *2/*3 to define subjects with intermediate
activity, while genotype *3/*3 defines low activity [7].
Interactions for a multiplicative effect between genes or
between environmental factors and genetic polymor-
phisms were tested with a case-only approach. The inter-
action OR with a case-only approach is noted as
prevalence odds ratio [15,16]. This approach requires ver-
ification that the distribution of the two factors (i.e.
genetic and environmental) is independent among con-
trols.
All reported values are 2-tailed.
Results
Table 1 presents the main characteristics of the subjects
included in the survey. The mean age of HCC cases was 62
years. Half were classified as blue-collar workers according
to the job title of their last job. Twenty-nine (21%) had
had a cirrhosis diagnosis for more than 5 years when HCC
was diagnosed, 42 (31%) for 1 to 4 years and 65 (48%)
simultaneously to or during the same year as the HCC
diagnosis. Serum samples of 151 HCC patients were
tested for virus markers, and 40 were positive. Seventeen
of these 40 were also heavy drinkers, while there were 102
heavy drinkers who were negative for virus markers
(62%). We therefore sub-classified the HCC cases in two
groups, those who were negative for virus markers — all
of whom were heavy drinkers (heavy drinker-Virus(-)) —
and those positive for virus markers, 42% of whom were
also heavy drinkers (Virus(+)).
Control patients with cirrhosis were slightly younger than
HCC cases (m = 58 ± 9 years), and 82 (62%) were blue-
collar workers. Distribution of time since cirrhosis diag-
nosis was similar to that of HCC cases with 21%, 35% and
43% of the cirrhosis patients diagnosed respectively for
more than 5 years, 1 to 4 years and during the year of the
interview. Cirrhosis was attributed to chronic alcohol use
for 106 patients negative for virus markers (79%). Twenty
subjects had serum samples positive for viral markers
(HBV or HCV or both), 10 of whom were also heavy
drinkers. We sub-classified the cirrhosis patients into the
same two groups as the HCC cases: those who had nega-
Table 1: Description of the population
Controls Cirrhosis HCC HCC vs Controls HCC vs Cirrhosis
N % N % N % OR 95%CI OR 95%CI
Age
< 50 11 7.7% 22 16.4% 17 10.3% 1.0 Ref 1.0 Ref
50–60 39 27.5% 63 47.0% 46 27.9% 0.8 0.3–1.9 1.0 0.5–2.1
60–70 56 39.4% 32 23.9% 61 37.0% 0.7 0.3–1.6 2.9 1.3–6.3
> 70 36 25.4% 17 12.7% 41 24.8% 0.7 0.3–1.8 3.8 1.6–9.3
142 134 165
m ± sd 62 ± 8.5 58 ± 8.6 62 ± 8.9
Hospital
K.-Bicêtre 53 37.3% 45 33.6% 48 29.1%
Bondy 48 34.0% 53 39.1% 60 36.4% - - - -
Nancy 13 9.0% 16 12.0% 25 15.1% - - - -
Beaujon 28 20.0% 20 15.0% 32 19.4% - - - -
142 134 165
Social class
White-collar worker 79 56.0% 49 38.0% 82 50.0% 1.0 Ref 1.0 Ref
Blue-collar worker 63 44.0% 80 62.0% 82 50.0% 1.3 0.8–2.0 0.6 0.3–0.9
142 129 164
Time since cirrhosis diagnosis
0–1 yr 53 43.4% 65 47.8% - - 1.0 Ref
> 1–< 5 43 35.2% 42 30.9% - - 0.8 0.4–1.5
> 5 26 21.3% 29 21.3% - - 0.8 0.4–1.5
122 136
Cirrhosis characteristics
Heavy drinkers-virus(-) 106 79.1% 102 61.8%
Virus(+) not heavy drinkers 101 7.5% 232 13.9%
Heavy drinkers-virus(+) 103 7.5% 174 10.3%
Hemochromatosis 1 0.7% 6 3.6%
other or unknown 7 5.2% 17 10.3%
165
1: 6 anti-HCV (+) 3 HbsAg (+) 1 both; 2: 20 anti-HCV (+) 2 HbsAg (+) 1 both ; 3:9 anti-HCV (+) 1 HbsAg (+); 4:15 anti-HCV (+) 2 HbsAg (+);BMC Cancer 2007, 7:214 http://www.biomedcentral.com/1471-2407/7/214
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tive virus markers, all of whom were heavy drinkers
(heavy drinker-Virus(-)), and those who had positive
virus markers, half of whom were heavy drinkers
(Virus(+)).
Controls with no liver disease were the same age as HCC
cases (m = 62 ± 8.5), and 63 (44%) were classified as blue-
collar workers.
Relations between HCC and known risk factors (alcohol 
and hepatitis)
Table 2 reports the distribution of controls, cirrhosis
patients and HCC cases according to their alcohol con-
sumption and includes the related OR estimates. Compar-
ing the HCC and control subjects shows that the OR
increased strongly with alcohol consumption. We esti-
mated an OR of 3.7 per unit of 10 drinks/day (p < 10-3).
The comparison between HCC and cirrhosis patients
showed no association with alcohol consumption, and
the OR per unit of 10 drinks per day was 1.07 (p = 0.7).
We also compared the prevalence of HbsAg and HCV anti-
bodies among subjects with HCC and those with cirrhosis
only and found, as expected, a higher prevalence of virus-
positive subjects among the subjects with HCC [OR = 3.1
(1.5–6.3)], with alcohol-induced cirrhosis as the reference
group.
Polymorphisms of xenobiotic metabolic enzymes
Table 3 presents the results of the UGT1A7 genotyping.
The alleles at the individual loci were in Hardy-Weinberg
equilibrium in all three groups.
Compared with the controls, HCC was not significantly
related to any of the different genotypes and all ORs were
less than 1. The negative ORs were not significant. Analy-
sis of the enzyme activity phenotype also showed no par-
ticular association between UGT1A7 polymorphism and
HCC. Distribution of the genotypes was similar for cirrho-
sis patients and controls. Accordingly, our comparison of
the genotype distribution in HCC and cirrhosis patients
again showed ORs less than 1 and not significant. Analysis
according to enzymatic activity showed an OR of 0.4
[0.1–1.1] for subjects defined with low activity (with high
activity as the reference).
Interestingly, the association between UGT1A7 and HCC
risk seemed to differ according to characteristics of cirrho-
sis. The initial comparison between HCC cases and con-
trols was restricted to HCC cases who were heavy drinkers
and virus(-). The relation with UGT1A7 was less than 1
and not significant, especially for subjects with low enzy-
matic activity [OR = 0.5 (0.2–1.2)]. But when we consid-
ered HCC cases who were virus(+), the OR of HCC for the
UGT1A7*3/*3 genotype was 2.3 (0.4–13.3). This pattern
of a rather negative OR among patients who were heavy
drinkers and virus(-) and a non-significant positive OR
among patients who were virus(+) was clearly reinforced
when we compared the HCC cases with the cirrhosis
patients. Among virus(+) subjects, the OR of HCC for the
UGT1A7*3/*3 genotype was 3.4 (0.3–45) and 2.2
(0.3–15) when we classified the subjects according to
enzymatic activity and 0.1 (0.02–0.6) (p = 0.01) and 0.2
(0.04–0.6) (p = 0,007) respectively, for virus(-) heavy-
drinking subjects. We estimated this interaction with a
case-only approach. We first verified that there was no
association between the two factors (presence of a viral
marker and UGT1A7 polymorphism — either genotypic
or phenotypic) among cirrhosis patients: the association
for the genotypic form of the UGT1A7 polymorphism had
a X2 = 4.7, p = 0.45 and the phenotypic form, X2 = 0.38, p
= 0.82. The prevalence odds ratio for virus(+) and
Table 2: Classic risk factors of HCC: Alcohol consumption and HBV/HBC
Controls (N = 142) Cirrhosis (N = 134) HCC (N = 165) HCC vs Controls HCC vs Cirrhosis
N%N%N% O R a 95%CI ORb 95%CI
Drinks/dayc
0–3 58 44,3% 17 14,0% 23 17,2% 1.0 Ref 1.0 Ref
3–7 38 29,0% 23 19,0% 26 19,4% 1.8 0.9–3.7 1.4 0.5–4.1
7–11 21 16,0% 25 20,7% 40 29,9% 4.9 2.4–10.2 2.7 0.9–7.5
≥ 11 14 10,7% 56 46,3% 45 33,6% 9.5 4.2–21.1 1.5 0.6–4.0
131c 100,0% 121c 100,0% 134c 100,0%
m ± sd 5.2d ± 5.2 11.2d ± 8.1 9.7d ± 9.4 3.7f 2.1–6.4 1.07f 0.97–1.5
m ± sd 3.3e ± 3.4 6.7e ± 8.3 5.1e ± 7.1
Cirrhosis characteristic
Heavy drinkers-virus(-) 106 84,1% 102 71,8% 1.0 Ref
Virus(+) 20 15,9% 40 28,2% 3.1 1.5–6.3
a: adjusted for age and hospital b: adjusted for age, hospital, time since cirrhosis diagnosis, origin of the cirrhosis (viral(+) or not), and social class c: 
alcohol variable missing for 50 subjects because the food frequency questionnaire was not available at the beginning of the study d: Lifetime mean 
consumption e: Consumption at the time of the interview. f: OR per unit of 10 drinks/dayBMC Cancer 2007, 7:214 http://www.biomedcentral.com/1471-2407/7/214
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UGT1A7 enzymatic activity was 2.3 (0.8–6.4) for the
intermediate activity category and 15.1 (2.7–84) (p =
0.002) for the low activity category. The same analysis
with the genotype data showed a prevalence odds ratio for
virus(+) and genetic polymorphism of 14.4 (2.0–103) (p
= 0.008) for the UGT1A7*3/*3 genotype.
Finally, we conducted an analysis that separated the
virus(+) subgroup into those who were not heavy drinkers
(i.e. 23 cases and 10 cirrhosis cf table 1) and those who
were. The results, despite the relatively small number of
subjects, show an OR of HCC associated with the geno-
type UGT1A7*3/*3 of 5.3 [0.2–153], but of 0.5 [0.02–12]
among those virus(+) subjects who were heavy drinkers.
Discussion
The aim of our study was to assess whether the UGT1A7
polymorphism might increase the risk of HCC. We con-
sidered 2 separate control groups. The first comprised
controls without liver disease to investigate whether these
genetic susceptibility factors were risk factors for hepatic
carcinoma. In addition, since almost all HCC in France
Table 3: Association between UGT1A7 and HCC
Controls Cirrhosis HCC HCC vs Controls HCC vs Cirrhosis
N%N % N %O R 1 95% CI OR2 95% CI
All
*1/*1 12 9.5% 11 8.2% 28 17.0% 1.0 Ref 1.0 Ref
*1/*2 27 20.6% 23 17.2% 31 18.8% 0.5 0.2–1.3 0.8 0.3–2.5
*1/*3 36 27.5% 36 26.9% 51 30.9% 0.8 0.3–2.0 0.8 0.3–2.3
*2/*2 9 6.9% 10 7.5% 12 7.3% 0.6 0.2–2.3 0.8 0.2–3.3
*2/*3 28 21.4% 31 23.1% 19 11.5% 0.4 0.1–1.2 0.3 0.1–1.2
*3/*3 19 14.5% 22 16.4% 23 13.9% 0.7 0.2–2.1 0.4 0.1–1.2
determined 131 133 164
H 48 33.8% 44 32.8% 71 43.0% 1.0 Ref 1.0 Ref
HL 64 45.1% 67 50.0% 70 42.4% 1.0 0.5–1.8 0.7 0.4–1.4
L 19 13.4% 22 16.4% 23 13.9% 1.2 0.5–2.6 0.4 0.2–1.0
131 133 164
Heavy drinkers virus(-)
*1/*1 7 6.5% 18 17.5% 1 Ref 1 Ref
*1/*2 17 15.9% 23 22.3% 0.7 0.2–2.3 0.7 0.2–3.0
*1/*3 29 27.1% 31 30.1% 1.1 0.4–3.2 0.5 0.1–2.0
*2/*2 10 9.3% 9 8.8% 1.1 0.3–4.4 0.5 0.1–2.4
*2/*3 27 25.2% 12 11.6% 0.4 0.1–1.5 0.2 0.04–0.7
*3/*3 17 15.9% 10 9.7% 0.5 0.2–1.9 0.1 0.02–0.6
determined 107 103
H 34 31.8% 50 48.5% 1.0 Ref 1.0 Ref
HL 56 52.3% 43 41.7% 0.6 0.3–1.1 0.5 0.2–1.1
L 17 15.9% 10 9.7% 0.5 0.2–1.2 0.2 0.04–0.6
107 103
Virus(+)
*1/*1 3 15.0% 6 15.0% 1.0 Ref 1.0 Ref
*1/*2 4 20.0% 6 15.0% 0.6 0.1–3.9 1.3 0.1–19.7
*1/*3 6 30.0% 11 27.5% 1.3 0.2–7.0 1.8 0.1–19.2
*2/*2 0 0.0% 3 7.5% 0.9 0.1–8.0 -
*2/*3 3 15.0% 4 10.0% 0.9 0.1–5.8 6.4 0.3–140
*3/*3 4 20.0% 10 25.0% 2.3 0.4–13.3 3.4 0.3–45
determined 20 40
H 7 35.0% 15 37.5% 1.0 Ref 1.0 Ref
HL 9 45.0% 15 37.5% 1.5 0.6–4.1 1.6 0.2–8.3
L 4 20.0% 10 25.0% 3.1 1.0–9.6 2.2 0.3–15.3
20 40
1: adjusted for age, hospital, drinks/day, social class.; 2: adjusted for age, hospital, drinks/day, social class, time since cirrhosis diagnosisBMC Cancer 2007, 7:214 http://www.biomedcentral.com/1471-2407/7/214
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occurs on cirrhotic liver, we also considered a control
group of patients with cirrhosis to investigate whether
these polymorphisms were risk factors for the transforma-
tion from cirrhosis to carcinoma.
The study we set up used a hospital-based approach. our
controls were selected from more than 13 departments to
avoid overrepresentation of a single disease that might be
related to the environmental or genetic risk factors we
were studying. We also included a second control group of
cirrhosis patients without HCC. Most cases of HCC
(approximately 90%) develop in cirrhotic liver, and time
is the principal risk factor: roughly 3–4% of cirrhosis
patients per year develop HCC. It was thus essential to
avoid comparing patients with newly diagnosed cirrhosis,
that is, who had not had enough time to develop HCC, to
HCC patients with cirrhosis diagnosed several years ear-
lier. We therefore stratified HCC and cirrhosis patients by
time since cirrhosis diagnosis and included newly diag-
nosed cirrhosis patients as controls only for HCC patients
whose cirrhosis was diagnosed at the same time as the car-
cinoma (stratum 1); cirrhosis patients diagnosed within
the past 5 years served as controls for HCC patients whose
cirrhoses were also diagnosed in that period (stratum 2),
and finally cirrhosis patients diagnosed more than 5 years
earlier (stratum 3) as controls for HCC patients whose cir-
rhoses were also diagnosed more than 5 years previously.
We evaluated subjects' history of alcohol consumption
except for the first 50 subjects, because the food frequency
questionnaire was not available at the time we started the
study. These data are therefore missing totally at random
and it is very likely that it did not create any selection bias
in the analysis of the different risk factors, particularly
genetic [17].
The results for UGT1A7 appear to be related to the charac-
teristics of cirrhosis. The genotypic frequencies that we
observed among our controls are very similar to those
reported by Guillemette et al. in a population of normal
healthy blood donors from the USA [14]. The alleles at the
individual loci were in Hardy-Weinberg equilibrium in all
three groups. In our comparisons between cases and con-
trols, we observed a non-significant positive OR with
UGT1A7*3/*3 when we restricted the analysis to virus(+)
subjects [OR = 2.3 (0.4–13.3)]. We obtained similar
results when we compared the virus(+) cases and the cir-
rhosis-viral(+) group [OR = 3.4 (0.3–45)]. These results
are consistent with Vogel's study, which reported a strong
association with the UGT1A7*3/*3 genotype [4]. We note
that the HCC patients in that study had mainly viral dis-
ease. A more recent case-control study in a population of
patients with viral HCC also found a relation between
UGT1A7 low enzymatic activity and HCC; its results are
quantitatively very similar to ours [2.0 (0.6–6.7) for the
UGT1A7*3/*3 genotype and 2.7 (1.4–5.3) for the low
enzymatic activity [5]. This result was again reproduced in
a third case-control study in a Taiwanese population
where HBV and HCV infections are endemic [6].
Inversely, we found a strong negative OR for this genotype
(UGT1A7*3/*3) when we considered HCC and cirrhosis
patients who were heavy drinkers and virus(-). Further-
more, our results show a strong positive association with
the UGT1A7*3/*3 genotype for those with viral markers
who were not heavy drinkers [OR = 5.3 (0.2–153)], a neg-
ative association among heavy drinkers with viral markers
[OR = 0.5 (0.02–12)], and finally a strong negative associ-
ation for heavy drinkers who were virus (-) [OR = 0.1
(0.02–0.6), p = 0.001]. These results seem extremely inter-
esting, despite the large confidence intervals.
Our case control study included a population of HCC and
cirrhosis patients, most of whom were heavy drinkers and
virus(-) (i.e. 79% of HCC patients and 62% of cirrhosis
patients). The distribution of the characteristics of the cir-
rhosis (i.e. virus(+) or heavy drinker-virus(-)) of our cases
and cirrhosis patients is markedly different from those
found in the three case control studies thus far published
[4-6]. Moreover the cirrhosis group was stratified accord-
ing to time since diagnosis so that we did not compare
HCC patients with cirrhosis patients who would not have
had time to develop a carcinoma.
Because HBV/HCV viral markers were not available for
controls, we used a case-only approach to assess the
hypothesis that the two categories of cases, distinguished
by the presence or the absence of the viral marker, were
characterized by etiological heterogeneity. Our result was
very strong [OR = 12.0 (1.6–92)], although its confidence
interval was very wide, when we tested interaction for the
*3/*3 genotype. Similarly, the prevalence OR associated
with the presence of viral markers was 15.2 (2.7–86)
when we tested interaction with phenotypic activity of
UGT1A7. Thus, despite the low p values, the observed
interaction may be due to chance. However, if true, this
interaction would imply that viral induced liver carcino-
genesis is favoured by the level of detoxifying UDPGT.
Functional characterization shows that the UGT1A7*3
allele has the lowest relative activity and UGT1A7*1 and
UGT1A7*2 the highest [7]. We have however no hypoth-
esis to explain the difference in the relation between HCC
and UGT1A7 according to cause of cirrhosis. The UGT1A7
polymorphism appears to be related to risks for other can-
cer sites, including the colon, pancreas, UADT, and mouth
and larynx [8-13]. There is no known viral etiology for any
of these cancer sites. Further studies are needed to confirm
these results and to explain why the same genotype (i.e.,
UGT1A7*3/*3) is more frequent in viral HCC patientsPublish with BioMed Central    and   every 
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and less frequent in alcohol-induced HCC patients com-
pared with their cause-matched cirrhotic patients.
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